AbbVie (ABBV) Tops Q4 EPS by 3c, Confirms Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
AbbVie (ABBV) PT Trimmed at Jefferies But Sees Excellent Entry Point
February 3, 2015 8:41 AM ESTJefferies analyst Jeffrey Holford reiterated a Buy rating on Abbvie (NYSE: ABBV) following Q4 results but lowered his price target to $80.00 (from $82.00). The firm said recent weakness creates an excellent entry point.
Holford commented, "We view ABBV's 2015 HCV guidance as conservative, which is... More
